Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders

Annals of Hepatology

Volumn 7, Issue 4, 2008, Pages 369-375

  Poo, Jorge L ^a   Ávila, Francisco Sánchez ^a   Kershenobich, David ^b   Samper, Xochitl García ^c   Torres Ibarra, Rocío ^d   Góngora, Julieta ^a   Cano, Carlos ^d   Parada, Miguel ^a   Uribe, Misael ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c HOSPITAL REGIONAL LIC ADOLFO LÓPEZ MATEOS   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Chronic hepatitis C; Nonresponders; Peginterferon 2a; Pegylated interferon; Ribavirin; Thymalfasin; Thymosin alpha 1; Triple therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; THYMOSIN ALPHA1; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS C; HISPANIC; HUMAN; INSOMNIA; LIVER BIOPSY; LIVER DISEASE; LIVER INJURY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PILOT STUDY; POLYMERASE CHAIN REACTION; PRURITUS; RECOMMENDED DRUG DOSE; RHINITIS; RNA ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS STRAIN;

EID: 56749097120     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31839-3     Document Type: Article

References (24)

1. Moscarella S, Buzzelli G, Romanelli RG, et al. Interferon and thymosin combination therapy in naïve patients with chronic hepatitis C: preliminary results. Liver 1998; 18: 366-9.
2. World Health Organization (WHO). Fact Sheet 164. Hepatitis C. Available at: www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 18, 2005.
3. Centers for Disease Control (CDC). Fact Sheet. Viral Hepatitis C. Available at: www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. Accessed July 20, 2005.
4. Valdespino JL, Olaiz G, Conde C, de Lourdes García M, Vierya A. Hepatitic C en México: resumen de cifras para tomadores de decisiones. Reto de Hepatitis C 2005.
5. Shiffman ML, Hoffman CM, Contos MJ, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117: 1164-72.
6. Shiffman ML, DiBisceglie AM, Lindsay KL, et al for the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group. Peginterferon α-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.
7. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
9. Thuluvath PJ, Maheshwari A, Mehdi J, et al. Randomized, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C. Gut 2004; 53: 130-5.
10. Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs inteferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. J Viral Hep 2005; 12: 292-9.
11. Adinolfi LE, Utili R, Tonziello A, Ruggiero G. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomized trial. Gut 2003; 52: 701-5.
12. Sherman KE, Sjogren M, Creager RL et al. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled doubleblind trial. Hepatology 1998; 27: 1128-35.
13. Iftikhar R, Di Bisceglie A, Pockros PJ, Rustgi VK, Schulman M, Martins EB. HCV RNA and immunological responses to thymalfasin in combination with peginterferon α-2a in HCV non-responders: a 12-week kinetic study. Presented at: 53rd Annual Meeting of the American Association for the Study of Liver Disease (AASLD); November 1-5, 2002; Boston, Mass. Abstract 790.
14. Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North Am 2004; 33(1 suppl): S1-S9.
15. Fried MW, Shiffman ML, Rajender Reddy K, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
16. Teuber G, Pascu M, Berg T, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphase in non-responders with chronic hepatitis C. J Hepatol 2003; 9: 606-13.
17. Knutsen AP, Freeman JJ, Mueller KR, et al. Thymosin-á1 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model. Int J Immunopharmacol 1999; 21: 15-26.
18. Andreone P, Cursaro C, Gramenzi A, et al. In vitro effect of thymosin-α 1 and interferon-α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 194-201.
19. Giuliani C, Napolitano G, Mastino A, et al. Thymosin-α1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 2000; 30: 778-86.
20. Rasi G, DiVirgilio D, Mutchnick MG, et al. Combination thymosin α1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 1996; 39: 679-83.
21. Poo JL, Sanchez-Avila F, Kershenobich D, Garcia-Samper X, Gongora J, Uribe M. Triple combination of thymalfasin, peginterferon α-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study. J Gastroenterol Hepatol 2004; 19: S79-S81.
22. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS, the Canadian Pegasys Study. Gut 2006; 55: 1631-1638, 2005.
23. Krawitt EL, Ashikaga T, Gordon SR, Ferrentino N, Ray MA, Lidofsky SD; New York New England Study Team. Peginterferon α-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43(2): 243-9.
24. Bruno S, Facciotto C. The natural course of HCV infection and the need for treatment. Ann Hepatol 2008; 7(2): 114-9.